Advanced Strategies and Best Practices for Predictive Pharmacokinetics using Simcyp™ Discovery
Refine your approach to early drug development with insights from industry experts in our upcoming webinar, “First-In-Human (FIH) Faster: The Power of Physiologically Based Pharmacokinetic Modeling (PBPK).” If you’re seeking strategies to identify and advance your small molecule drug candidates, expedite product profiling, formulation, and dose recommendations, and seamlessly integrate in vitro, physchem, and preclinical data into insilico tools, this is a must-attend event.
Join our expert panel as we explore the potential of advanced PBPK modeling, showcasing how Simcyp Discovery leverages existing data to guide decisions supporting Investigational New Drug Application (IND) submissions. Our best practices empower pre-clinical teams to seamlessly translate in vitro data into reliable predictions of pharmacokinetics (PK) and pharmacodynamics (PD) in animal models and human dosing, increasing confidence in decision making. This not only reduces time and costs but also mitigates ethical complications associated with imperfectly planned in vivo studies.
Webinar Highlights:
- PBPK Best Practices: Explore how PBPK modeling allows understanding ADME processes, translating in vitro data into precise predictions for animal models and human dosing.
- Insights from Experts: Gain firsthand experiences leveraging Simcyp Discovery for better informed human trials.
Key Takeaways:
- User Experience and Consultancy Insights
- FIH Dose Prediction Process
- Process Enhancements and Streamlining
- Best Practices in Early Discovery
- Choosing Between In Vitro/Animal Studies and Modeling
- IND Applications and Impact of PBPK Modeling
Panelists:
Masoud Jamei, SVP, Research and Development
Hannah Jones, SVP, PBPK Consultancy
Kevin Romer, VP (Simcyp)
Himanshu Mishra, Director (Simcyp)
Freddy Chen, Principal PBPK Consultant
Don’t miss the opportunity to learn tips to boost confidence in early-stage drug development decisions!